

OFFICE OF HUMAN RESEARCH PROTECTION PROGRAMME  
(OHRPP)

9c. DSRB FULL BOARD REVIEW CATEGORIES  
& REVIEW CRITERIA  
BIOMEDICAL DOMAINS A-E  
&  
POPULATION HEALTH – DOMAIN F

*Reference:*

*NHG Investigator Manual*

*NHG Group Research*

*Version November 2022*



Adding years of healthy life

# DSRB Review Categories – Full Board

## 3 routes of review




**In general, the determination is based on the level of risk in which research participants are exposed to. Taking into other considerations, DSRB may escalate the category of review as needed.**

*Refer to Chapter 4.3 of the NHG Investigator Manual for all categories and more examples.*


# DSRB Review Category – Full Board

Research proposals that do not qualify for exempt or expedited review will be reviewed by the Full Board process.

In general, research studies that involve more than minimal risk will undergo Full Board review. Such studies may include research studies that are studying the safety and efficacy of a medicinal product or medical device, or research studies that involve invasive procedures.




# DSRB Review Category – Full Board



Examples of research that may qualify for FB review:

- Research studies (i.e. Clinical Trials) that involve the study of the safety and efficacy of a medicinal product, medical device or research study that involve invasive procedures.

# DSRB Review Category For **Population Health (Domain F)** – Full Board



Example of research that may qualify for Population Health (Domain F) Full Board review:

- High risk research studies involving evaluation of new exercise programme in elderly that will improve overall health of the participants.

**Note: Population Health (Domain F) does not review clinical trial.**

# REVIEW CRITERIA

Submitted ROAM application will be reviewed, adhering to the following review criteria:

1. **Risks** to participants are **minimised**.
2. **Risks** to participants are **reasonable** in **relation** **anticipated benefits** (if any) to subjects.
3. **Selection** of participants is **equitable**.
4. **\*Informed consent** will be sought from each prospective participant or the participant's legally acceptable representative.

*\*Patient information sheet must be submitted.*

# REVIEW CRITERIA

5. **Informed consent** will be appropriately **documented**.
6. Adequate provision for **monitoring the data** collected to ensure the safety of participants.
7. Adequate provisions to protect the **privacy** of participants and maintain the confidentiality of data.
8. Additional safeguards incorporated for **vulnerable populations**.
9. The Human Biomedical Research Act prohibits the commercial trading of human tissue (whether for research, therapy or any other purpose). Therefore, the DSRB will not approve any research that involves the use of human tissues that are purchased commercially

## *Reference:*

*45 CFR 46.111 (a) and 21 CFR 56.111 & NHG Investigator Manual Chapter 4.3.2 Review Considerations and Criteria*

# Questions?

Refer to [www.research.nhg.com.sg](http://www.research.nhg.com.sg)

Or contact the NHG Research  
Education Unit @  
researchcoord@nhg.com.sg